bioAffinity Technologies, Inc.
BIAFHealthcareNASDAQDiagnostics & Research · Last scanned Oct 27, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, bioAffinity Technologies, Inc. focuses on Diagnostics & Research services and products. bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The $3.6M market capitalization puts BIAF squarely in micro-cap range for its industry. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.
Market Cap
$3.6M
Beta
-1.25
P/E (TTM)
—
P/E (Fwd)
-4.72
EPS (TTM)
$-109.35
EPS (Fwd)
$-0.60
ROE
-1860.2%
ROA
-125.1%
Cash
$2.4M
Total Debt
$1.4M
Free CF
-$6.9M
52W Change
-92.7%
Annual Financials
Cash vs Debt
Where BIAF stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BIAF finished 83.08% below its 150-day moving average ($20.74) and 82.42% below its 200-day moving average ($19.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BIAF overbought or oversold?
At the October 20, 2026 close, BIAF's RSI(14) was 13.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $2.4M in cash and $1.4M in debt, BIAF maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$6.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -1860.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $5K (2022) to $6.1M (2025), reflecting a 127070% increase over the period.
The relatively low beta of -1.25 suggests BIAF is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BIAF.